DaVita Inc. $DVA Stake Raised by Sei Investments Co.

Key Points

• Sei Investments Co. increased its ownership in DaVita Inc. by 4% during the first quarter, holding approximately $14.43 million worth of the company's stock.
• DaVita reported a quarterly EPS of $2.95, exceeding analysts' expectations of $2.70, with revenue rising 6.1% year-over-year to $3.38 billion.
• Insider James O. Hearty sold 2,351 shares of DaVita at an average price of $150.00, reducing his ownership stakes in the company.

Sei Investments Co. increased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,411 shares of the company's stock after buying an additional 3,642 shares during the period. Sei Investments Co. owned 0.12% of DaVita worth $14,428,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. UMB Bank n.a. raised its position in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Copia Wealth Management acquired a new position in DaVita during the fourth quarter worth $30,000. National Pension Service lifted its holdings in shares of DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after purchasing an additional 84 shares in the last quarter. Y.D. More Investments Ltd bought a new stake in DaVita in the 1st quarter valued at $35,000. Finally, Coppell Advisory Solutions LLC boosted its position in shares of DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.50% of the company's stock.

DaVita Trading Up 0.7%

DaVita stock traded up $0.96 during mid-day trading on Friday, hitting $135.35. The company's stock had a trading volume of 721,001 shares, compared to its average volume of 925,686. The firm has a market capitalization of $9.68 billion, a PE ratio of 13.31, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09. The stock's fifty day moving average is $139.68 and its two-hundred day moving average is $145.06. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1 year low of $126.07 and a 1 year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the business posted $2.00 EPS. The company's revenue for the quarter was up 6.1% on a year-over-year basis. On average, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DVA shares. Barclays reduced their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.